0

Close
 
2022
Ulcerative Colitis Market

Ulcerative Colitis Market

by Disease Type (Mild UC, Moderate UC, Severe UC), by Molecule Type (Biologics, Small Molecules), by Route of Administration (Oral, Injectables): Global Opportunity Analysis and Industry Forecast, 2021-2030
Update Available On-Demand

LS : Pharmaceuticals
✷  Report Code: A03620
Mar 2022 | Pages: 225
Tables: 124
Charts: 56

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Ulcerative Colitis Market Research, 2030

The global ulcerative colitis market was valued at $6.2 billion in 2020, and is projected to reach $10.8 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Ulcerative colitis is a most common form of inflammatory bowel disease which affects several people.  It causes inflammation and ulcers in digestive tract. Ulcerative colitis affects the innermost lining of large intestine and rectum. Ulcerative colitis develops at any age, but is commonly developed in people between the age of 15 and 30. The symptoms of ulcerative colitis vary from person to person and may include diarrhea, passing blood with your stool, and abdominal immune response.

The impact of the COVID-19 pandemic on the ulcerative colitis market was reported to be negative, due to COVID-19, patients forced to postpone or cancel elective surgery, including elective procedures for inflammatory bowel disease (IBD), despite the higher risk of these patients of requiring urgent surgery. So, the delay the procedures of ulcerative colitis treatment decrease the production of medications over ulcerative colitis disease has restricted the growth of the market.

Ulcerative Colitis Market

Growth of the global ulcerative colitis market is majorly driven by increase in prevalence of inflammatory gastrointestinal disorders, increase in the cases of ulcerative colitis, and development of drugs for treatment of ulcerative colitis by large number of key players. According to a survey conducted by Marc D Basson on Ulcerative Colitis in 2019, in the U.S., one million people were affected with ulcerative colitis. Prevalence of ulcerative colitis is the main reason for development of drugs to treat ulcerative colitis. Thus, with rise in burden of inflammatory bowel disease demand for ulcerative colitis increases, which, in turn, is anticipated to foster the growth of the ulcerative colitis market. Furthermore, according to a research study by Wing Yan Mak et al. published in Journal of Gastroenterology and Hepatology, in 2020, in Europe, North America, and Australia 23-34% of ulcerative colitis patients presented were with proctitis. In addition, in May 2021, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration for the use of  Zeposia for treating adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. Therefore, rise in development of new drugs led to increase in the growth of the ulcerative colitis market opportunity.

Ulcerative colitis market segmentation

The ulcerative colitis market is segmented on the basis of route of administration, disease type, and molecule type. Depending on route of administration, it is categorized into oral and injectables.

According to disease type, it is classified into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis. By molecule type, it is divided into small molecules and biologics.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Ulcerative Colitis Market
By Route Of Administration

Your browser does not support the canvas element.

Injectables segment would witness the fastest growth, registering a CAGR of 6.4% during the forecast period.

Get more information on this report : Request Sample Pages

Depending on route of administration, the oral segment dominated the ulcerative colitis market forecast, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical & medical device industry, rise in demand for drugs required for treatment, and surge in adoption of various types of ulcerative colitis drugs. However, the injectables segment is expected to witness considerable growth during the forecast period, owing to increase in number of ulcerative colitis cases and growth in number of key players for development of new drugs in the medical device industry.

Ulcerative Colitis Market
By Disease Type

Your browser does not support the canvas element.

Moderate UC segment is projected to be the dominating segment throughout the forecast period.

Get more information on this report : Request Sample Pages

By disease type, the mild UC segment was the major contributor in 2020, and is expected to maintain its lead of ulcerative colitis market share during the forecast period, owing to increase in number of inflammatory bowel diseases, rise in the number of ulcerative colitis, and increase in demand for the treatment of ulcerative colitis. However, the moderate UC is expected to witness considerable ulcerative colitis market growth during the forecast period due to increase in number of ulcerative proctitis and rise in development of new ulcerative colitis drugs in the clinical laboratories. These are the factors which is bossting the ulcerative colitis market size.

Ulcerative Colitis Market
By Molecule Type

Your browser does not support the canvas element.

Small Molecules segment would exhibit a CAGR of 6.2% during forecast period.

Get more information on this report : Request Sample Pages

On the basis of molecule type, the small molecule segment dominated the ulcerative colitis industry in 2020, and this trend is expected to continue during the forecast period, owing to large number key players offering drugs for treatment of ulcerative colitis and advancement in R&D activities. However, the biologics segment is expected to witness considerable growth during the forecast period, owing to increase in inflammatory gastrointestinal diseases and surge in usage of ulcerative colitis drugs.

Ulcerative Colitis Market
By Region

2030
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.5% during the forecast period.

Get more information on this report : Request Sample Pages

Region wise, North America dominated the market in 2020, and is expected to be dominant during the forecast period, owing to rise in number of ulcerative colitis disease, presence of key players, development of the healthcare sector, and presence of new  drugs in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.5% from 2021 to 2030, owing to increase in prevalence of inflammatory bowel disease and development of healthcare infrastructure.

The key players that operate in the global ulcerative colitis market include Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ulcerative colitis market analysis from 2020 to 2030 to identify the prevailing ulcerative colitis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the ulcerative colitis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global ulcerative colitis market trends, key players, market segments, application areas, and market growth strategies.

 Ulcerative Colitis Market Report Highlights

Aspects Details
Market Size By 2030 USD 10.8 billion
Growth Rate CAGR of 5.7%
Forecast period 2020 - 2030
Report Pages 225
By Disease Type
  • Mild UC
  • Moderate UC
  • Severe UC
By Molecule Type
  • Biologics
  • Small Molecules
By Route of Administration
  • Oral
  • Injectables
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Pfizer Inc., GLAXOSIMITHKLINE PLC, AstraZeneca plc, Abbott Laboratories, JOHNSON & JOHNSON, INDEX PHARMACEUTICALS HOLDINGS AB, SANOFI S.A, Merck & Co. Inc., ELI-LILLY, AJINOMOTO CO. INC.

Analyst Review

This section provides opinions of top level CXOs in the ulcerative colitis market. According to the insights of CXOs, increase in number of inflammatory bowel disease, rise in geriatric population, and advancements in new drug launches are all attributed to propel growth of the ulcerative colitis market.

 

CXOs further added increase in consumer awareness & demand for preventive healthcare services, rise in demand for healthcare services from overall population, and new advancements in disease treatment are predicted to broaden ulcerative colitis clinical applications. In addition,  increase in  number of products approval contributes toward growth of the market.

 

The market gains interest of healthcare companies, owing to focus on preventive facilities provided to patients who undergo critical inflammatory bowel disease treatment which are more complex than other health conditions. This leads to increase in utilization of ulcerative colitis drugs ,which provides lucrative opportunity for the growth of the market.

 

North America is expected to witness highest growth, in terms of revenue, owing to rise in geriatric population, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register fastest CAGR during the forecast period, owing to increase in number of inflammatory gastrointestinal disease and unmet needs for innovative ulcerative colitis drugs. However, stringent government regulations toward approval of biosimilars restrain the market growth during the forecast period.

 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Increase in prevalence of inflammatory gastrointestinal disorders

      • 3.4.2. Restraints

        • 3.4.2.1. Side effect associated with drug

      • 3.4.3. Opportunities

        • 3.4.3.1. Advancement in healthcare

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: ULCERATIVE COLITIS MARKET, BY DISEASE TYPE

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Mild UC

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Moderate UC

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Severe UC

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

  • CHAPTER 5: ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Biologics

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Small Molecules

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

  • CHAPTER 6: ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Oral

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Injectables

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

  • CHAPTER 7: ULCERATIVE COLITIS MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Disease Type

      • 7.2.3. Market size and forecast, by Molecule Type

      • 7.2.4. Market size and forecast, by Route of Administration

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Disease Type
          • 7.2.5.1.3. Market size and forecast, by Molecule Type
          • 7.2.5.1.4. Market size and forecast, by Route of Administration
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Disease Type
          • 7.2.5.2.3. Market size and forecast, by Molecule Type
          • 7.2.5.2.4. Market size and forecast, by Route of Administration
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Disease Type
          • 7.2.5.3.3. Market size and forecast, by Molecule Type
          • 7.2.5.3.4. Market size and forecast, by Route of Administration

    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Disease Type

      • 7.3.3. Market size and forecast, by Molecule Type

      • 7.3.4. Market size and forecast, by Route of Administration

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Disease Type
          • 7.3.5.1.3. Market size and forecast, by Molecule Type
          • 7.3.5.1.4. Market size and forecast, by Route of Administration
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Disease Type
          • 7.3.5.2.3. Market size and forecast, by Molecule Type
          • 7.3.5.2.4. Market size and forecast, by Route of Administration
        • 7.3.5.3. U.K.
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Disease Type
          • 7.3.5.3.3. Market size and forecast, by Molecule Type
          • 7.3.5.3.4. Market size and forecast, by Route of Administration
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Disease Type
          • 7.3.5.4.3. Market size and forecast, by Molecule Type
          • 7.3.5.4.4. Market size and forecast, by Route of Administration
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Disease Type
          • 7.3.5.5.3. Market size and forecast, by Molecule Type
          • 7.3.5.5.4. Market size and forecast, by Route of Administration
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Disease Type
          • 7.3.5.6.3. Market size and forecast, by Molecule Type
          • 7.3.5.6.4. Market size and forecast, by Route of Administration

    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Disease Type

      • 7.4.3. Market size and forecast, by Molecule Type

      • 7.4.4. Market size and forecast, by Route of Administration

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Disease Type
          • 7.4.5.1.3. Market size and forecast, by Molecule Type
          • 7.4.5.1.4. Market size and forecast, by Route of Administration
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Disease Type
          • 7.4.5.2.3. Market size and forecast, by Molecule Type
          • 7.4.5.2.4. Market size and forecast, by Route of Administration
        • 7.4.5.3. India
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Disease Type
          • 7.4.5.3.3. Market size and forecast, by Molecule Type
          • 7.4.5.3.4. Market size and forecast, by Route of Administration
        • 7.4.5.4. Australia
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Disease Type
          • 7.4.5.4.3. Market size and forecast, by Molecule Type
          • 7.4.5.4.4. Market size and forecast, by Route of Administration
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Disease Type
          • 7.4.5.5.3. Market size and forecast, by Molecule Type
          • 7.4.5.5.4. Market size and forecast, by Route of Administration
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Disease Type
          • 7.4.5.6.3. Market size and forecast, by Molecule Type
          • 7.4.5.6.4. Market size and forecast, by Route of Administration

    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Disease Type

      • 7.5.3. Market size and forecast, by Molecule Type

      • 7.5.4. Market size and forecast, by Route of Administration

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Disease Type
          • 7.5.5.1.3. Market size and forecast, by Molecule Type
          • 7.5.5.1.4. Market size and forecast, by Route of Administration
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Disease Type
          • 7.5.5.2.3. Market size and forecast, by Molecule Type
          • 7.5.5.2.4. Market size and forecast, by Route of Administration
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Disease Type
          • 7.5.5.3.3. Market size and forecast, by Molecule Type
          • 7.5.5.3.4. Market size and forecast, by Route of Administration
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Disease Type
          • 7.5.5.4.3. Market size and forecast, by Molecule Type
          • 7.5.5.4.4. Market size and forecast, by Route of Administration

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2020

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

    • 9.2. AJINOMOTO CO. INC.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

    • 9.3. AstraZeneca plc

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

    • 9.4. ELI-LILLY

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

    • 9.5. INDEX PHARMACEUTICALS HOLDINGS AB

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

    • 9.6. GLAXOSIMITHKLINE PLC

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

    • 9.7. JOHNSON & JOHNSON

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

    • 9.8. Merck & Co. Inc.

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

    • 9.9. Pfizer Inc.

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. SANOFI S.A

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

  • LIST OF TABLES

  • TABLE 01. GLOBAL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 02. ULCERATIVE COLITIS MARKET FOR MILD UC, BY REGION, 2020-2030 ($MILLION)
    TABLE 03. ULCERATIVE COLITIS MARKET FOR MODERATE UC, BY REGION, 2020-2030 ($MILLION)
    TABLE 04. ULCERATIVE COLITIS MARKET FOR SEVERE UC, BY REGION, 2020-2030 ($MILLION)
    TABLE 05. GLOBAL ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 06. ULCERATIVE COLITIS MARKET FOR BIOLOGICS, BY REGION, 2020-2030 ($MILLION)
    TABLE 07. ULCERATIVE COLITIS MARKET FOR SMALL MOLECULES, BY REGION, 2020-2030 ($MILLION)
    TABLE 08. GLOBAL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 09. ULCERATIVE COLITIS MARKET FOR ORAL, BY REGION, 2020-2030 ($MILLION)
    TABLE 10. ULCERATIVE COLITIS MARKET FOR INJECTABLES, BY REGION, 2020-2030 ($MILLION)
    TABLE 11. ULCERATIVE COLITIS MARKET, BY REGION, 2020-2030 ($MILLION)
    TABLE 12. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 13. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 14. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 15. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 16. U.S. ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 17. U.S. ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 18. U.S. ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 19. CANADA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 20. CANADA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 21. CANADA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 22. MEXICO ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 23. MEXICO ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 24. MEXICO ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 25. EUROPE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 26. EUROPE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 27. EUROPE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 28. EUROPE ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 29. GERMANY ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 30. GERMANY ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 31. GERMANY ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 32. FRANCE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 33. FRANCE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 34. FRANCE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 35. U.K. ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 36. U.K. ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 37. U.K. ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 38. ITALY ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 39. ITALY ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 40. ITALY ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 41. SPAIN ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 42. SPAIN ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 43. SPAIN ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 44. REST OF EUROPE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 45. REST OF EUROPE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 46. REST OF EUROPE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 47. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 48. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 49. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 50. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 51. JAPAN ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 52. JAPAN ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 53. JAPAN ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 54. CHINA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 55. CHINA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 56. CHINA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 57. INDIA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 58. INDIA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 59. INDIA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 60. AUSTRALIA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 61. AUSTRALIA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 62. AUSTRALIA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 63. SOUTH KOREA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 64. SOUTH KOREA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 65. SOUTH KOREA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 66. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 67. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 68. REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 69. LAMEA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 70. LAMEA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 71. LAMEA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 72. LAMEA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 73. BRAZIL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 74. BRAZIL ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 75. BRAZIL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 76. SAUDI ARABIA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 77. SAUDI ARABIA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 78. SAUDI ARABIA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 79. SOUTH AFRICA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 80. SOUTH AFRICA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 81. SOUTH AFRICA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 82. REST OF LAMEA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
    TABLE 83. REST OF LAMEA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2020-2030 ($MILLION)
    TABLE 84. REST OF LAMEA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
    TABLE 85. ABBOTT LABORATORIES: KEY EXECUTIVES
    TABLE 86. ABBOTT LABORATORIES: COMPANY SNAPSHOT
    TABLE 87. ABBOTT LABORATORIES: PRODUCT SEGMENTS
    TABLE 88. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 89. AJINOMOTO CO. INC.: KEY EXECUTIVES
    TABLE 90. AJINOMOTO CO. INC.: COMPANY SNAPSHOT
    TABLE 91. AJINOMOTO CO. INC.: PRODUCT SEGMENTS
    TABLE 92. AJINOMOTO CO. INC.: PRODUCT PORTFOLIO
    TABLE 93. ASTRAZENECA PLC: KEY EXECUTIVES
    TABLE 94. ASTRAZENECA PLC: COMPANY SNAPSHOT
    TABLE 95. ASTRAZENECA PLC: PRODUCT SEGMENTS
    TABLE 96. ASTRAZENECA PLC: PRODUCT PORTFOLIO
    TABLE 97. ELI-LILLY: KEY EXECUTIVES
    TABLE 98. ELI-LILLY: COMPANY SNAPSHOT
    TABLE 99. ELI-LILLY: PRODUCT SEGMENTS
    TABLE 100. ELI-LILLY: PRODUCT PORTFOLIO
    TABLE 101. INDEX PHARMACEUTICALS HOLDINGS AB: KEY EXECUTIVES
    TABLE 102. INDEX PHARMACEUTICALS HOLDINGS AB: COMPANY SNAPSHOT
    TABLE 103. INDEX PHARMACEUTICALS HOLDINGS AB: PRODUCT SEGMENTS
    TABLE 104. INDEX PHARMACEUTICALS HOLDINGS AB: PRODUCT PORTFOLIO
    TABLE 105. GLAXOSIMITHKLINE PLC: KEY EXECUTIVES
    TABLE 106. GLAXOSIMITHKLINE PLC: COMPANY SNAPSHOT
    TABLE 107. GLAXOSIMITHKLINE PLC: PRODUCT SEGMENTS
    TABLE 108. GLAXOSIMITHKLINE PLC: PRODUCT PORTFOLIO
    TABLE 109. JOHNSON & JOHNSON: KEY EXECUTIVES
    TABLE 110. JOHNSON & JOHNSON: COMPANY SNAPSHOT
    TABLE 111. JOHNSON & JOHNSON: PRODUCT SEGMENTS
    TABLE 112. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
    TABLE 113. MERCK & CO. INC.: KEY EXECUTIVES
    TABLE 114. MERCK & CO. INC.: COMPANY SNAPSHOT
    TABLE 115. MERCK & CO. INC.: PRODUCT SEGMENTS
    TABLE 116. MERCK & CO. INC.: PRODUCT PORTFOLIO
    TABLE 117. PFIZER INC.: KEY EXECUTIVES
    TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
    TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
    TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
    TABLE 121. SANOFI S.A: KEY EXECUTIVES
    TABLE 122. SANOFI S.A: COMPANY SNAPSHOT
    TABLE 123. SANOFI S.A: PRODUCT SEGMENTS
    TABLE 124. SANOFI S.A: PRODUCT PORTFOLIO

  • LIST OF FIGURES

  • FIGURE 1.ULCERATIVE COLITIS MARKET SEGMENTATION
    FIGURE 2.ULCERATIVE COLITIS MARKET,2020-2030
    FIGURE 3.ULCERATIVE COLITIS MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.ULCERATIVE COLITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.ULCERATIVE COLITIS MARKET,BY DISEASE TYPE,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF MILD UC ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MODERATE UC ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEVERE UC ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 15.ULCERATIVE COLITIS MARKET,BY MOLECULE TYPE,2020(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 18.ULCERATIVE COLITIS MARKET,BY ROUTE OF ADMINISTRATION,2020(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ORAL ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INJECTABLES ULCERATIVE COLITIS MARKET,2020-2030(%)
    FIGURE 21.ULCERATIVE COLITIS MARKET BY REGION,2020
    FIGURE 22.U.S. ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 23.CANADA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 24.MEXICO ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 25.GERMANY ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 26.FRANCE ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 27.U.K. ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 28.ITALY ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 29.SPAIN ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 30.REST OF EUROPE ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 31.JAPAN ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 32.CHINA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 33.INDIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 34.AUSTRALIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 35.SOUTH KOREA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 36.REST OF ASIA-PACIFIC ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 37.BRAZIL ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 38.SAUDI ARABIA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 39.SOUTH AFRICA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 40.REST OF LAMEA ULCERATIVE COLITIS MARKET,2020-2030($MILLION)
    FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 45.COMPETITIVE DASHBOARD
    FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
    FIGURE 48.AJINOMOTO CO. INC..: NET SALES ,($MILLION)
    FIGURE 49.ASTRAZENECA PLC.: NET SALES ,($MILLION)
    FIGURE 50.ELI-LILLY.: NET SALES ,($MILLION)
    FIGURE 51.INDEX PHARMACEUTICALS HOLDINGS AB.: NET SALES ,($MILLION)
    FIGURE 52.GLAXOSIMITHKLINE PLC.: NET SALES ,($MILLION)
    FIGURE 53.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
    FIGURE 54.MERCK & CO. INC..: NET SALES ,($MILLION)
    FIGURE 55.PFIZER INC..: NET SALES ,($MILLION)
    FIGURE 56.SANOFI S.A.: NET SALES ,($MILLION)

 
 

Ulcerative colitis (UC) is the gastrointestinal disease of the colon for which etiology is still unknow. The market for ulcerative colitis is driven by several unmet needs in the treatment of UC. This is since the prevalence of ulcerative colitis is high in Latin America, India, China and western countries. However, there not many drugs approved in these countries and some of which are approved and not adopted due to lack of awareness and improper healthcare infrastructural development. In this regard, many key players have invested in the R&D of ulcerative colitis drug development. This has led to the emergence of biologics in development of drugs for UC treatment.

Biologics are engineered drugs that specifically target an immune or genetic mediator of a given disease. Infliximab is one of the biologic commonly used for treatment of ulcerative colitis. Moreover, many drugs are in the pipeline for approval or are under clinical trials. Hence, increase focus of key players in drug development, rise in UC prevalence and continuous clinical trials carried out for bringing novel drugs to the market are the factors that are accelerating the ulcerative colitis market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The upcoming trends of Ulcerative Colitis Market are large number key players offering drugs for treatment of ulcerative colitis and advancement in R&D activities, also increase in number of inflammatory bowel diseases, rise in the number of ulcerative colitis, and increase in demand for the treatment of ulcerative colitis.

A. The leading application of Ulcerative Colitis Market are mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis.

A. North America is the largest regional market for Ulcerative Colitis.

A. Ulcerative Colitis is estimated to reach $1,764.66 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030.

A. The top companies to hold the market share in Ulcerative Colitis are Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Ulcerative Colitis Market

Start reading instantly.
This Report and over 68,113+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers